<span item_type="fundamental" item_id="b3f536ffa4871cef7250d1f008746289" counter_id="ST/US/ZURA" env="prod"></span><span item_type="announcement" item_id="582290132270781953" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.21.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -21.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: The company has not generated any revenue from product sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>:<ul><li>For the three months ended September 30, 2025: - $18.0 million</li><li>For the nine months ended September 30, 2025: - $51.5 million</li><li>For the three months ended September 30, 2024: - $20.7 million</li><li>For the nine months ended September 30, 2024: - $38.8 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>Research and Development Expenses</strong>:<ul><li>For the three months ended September 30, 2025: $11.9 million</li><li>For the nine months ended September 30, 2025: $31.1 million</li><li>For the three months ended September 30, 2024: $6.0 million</li><li>For the nine months ended September 30, 2024: $15.2 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>General and Administrative Expenses</strong>:<ul><li>For the three months ended September 30, 2025: $7.6 million</li><li>For the nine months ended September 30, 2025: $25.7 million</li><li>For the three months ended September 30, 2024: $13.3 million</li><li>For the nine months ended September 30, 2024: $24.3 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>:<ul><li>For the nine months ended September 30, 2025: - $42.5 million</li><li>For the nine months ended September 30, 2024: - $17.3 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>Net Cash Used in Investing Activities</strong>:<ul><li>For the nine months ended September 30, 2025: - $0.1 million</li><li>For the nine months ended September 30, 2024: - $5.0 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>Net Cash Provided by Financing Activities</strong>:<ul><li>For the nine months ended September 30, 2025: $5.2 million</li><li>For the nine months ended September 30, 2024: $110.7 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li></ul><h3>Unique Metrics</h3><ul><li><strong>Share-Based Compensation Expense</strong>:<ul><li>For the three months ended September 30, 2025: $2.4 million</li><li>For the nine months ended September 30, 2025: $9.8 million</li><li>For the three months ended September 30, 2024: $8.6 million</li><li>For the nine months ended September 30, 2024: $14.0 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>Accretion of Redeemable Noncontrolling Interest to Redemption Value</strong>:<ul><li>For the three months ended September 30, 2025: - $2.8 million</li><li>For the nine months ended September 30, 2025: - $2.8 million</li><li>For the three months ended September 30, 2024: - $2.2 million</li><li>For the nine months ended September 30, 2024: - $4.6 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li><li><strong>Adjustment of Redeemable Noncontrolling Interest</strong>:<ul><li>For the three months ended September 30, 2025: $0.8 million</li><li>For the nine months ended September 30, 2025: $0.8 million</li><li>For the three months ended September 30, 2024: $0</li><li>For the nine months ended September 30, 2024: $7.0 million<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>Clinical Trials</strong>: The company is advancing its lead product candidate, tibulizumab, in ongoing Phase 2 clinical trials for hidradenitis suppurativa (HS) and early diffuse cutaneous systemic sclerosis (dcSSc). Topline results for these trials are expected in the third quarter of 2026 and the fourth quarter of 2026, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li><li><strong>Pipeline Development</strong>: The company is evaluating additional development opportunities for its other product candidates, crebankitug and torudokimab, focusing on indications with unmet need and commercial potential.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li><strong>Licensing Agreements</strong>: The company has entered into various licensing agreements, including the 2023 Lilly License and the 2022 Lilly License, which involve milestone payments and royalties based on the development and commercialization of product candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li><li><strong>ATM Program</strong>: The company has an active ATM program with $114.0 million of Class A Ordinary Shares remaining available for sale under the Sales Agreement as of the date of the filing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul><h3>Priority</h3><ul><li><strong>Financial Management</strong>: The company has raised significant funds through equity sales and private placements, ensuring sufficient liquidity to fund operations through 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li><li><strong>Regulatory Compliance</strong>: The company is focused on maintaining compliance with regulatory requirements and advancing its clinical trials to achieve regulatory approval for its product candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm"></span></li></ul>

Zura Bio | 10-Q: FY2025 Q3 Revenue: USD 0